After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...
With the approval of the FDA, garadacimab can help patients with hereditary angioedema (HAE) prevent attacks by shutting down the contact pathway. Today, the FDA approved CSL’s garadacimab-gxii ...
SAN ANTONIO -- Among patients with hereditary angioedema (HAE), monthly injections of the investigational biologic garadacimab reduced the mean attack rate substantially in the phase III VANGUARD ...
Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2025 investor letter. A ...
Despite the availability of long-term prophylaxis (LTP), a substantial proportion of patients with hereditary angioedema (HAE) in Sweden continue to require repeated on-demand or short-term treatments ...
Initial findings from a Phase 3 efficacy trial suggest Ionis Pharmaceuticals’ RNA-targeted treatment, given monthly or bimonthly, cut angioedema attacks more than placebo, the firm said Monday. The ...
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...
Haemonetics (HAE) has been beaten down lately with too much selling pressure. While the stock has lost 5.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results